EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia
September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou
Updated on: October 11,2023
148
EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia
September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou
Updated on:October 11,2023
148